Flagship Pioneering committed an initial £100 million on 16 November to establish a London lab for creating AI-driven biotech companies, its first company-creation unit outside the United States. The Cambridge, Massachusetts-based venture firm said in its announcement that it expects the commitment to attract an additional £500 million through partnerships.
Key points
- Flagship has committed an initial £100 million to its London company-creation lab.
- The firm expects partnerships to bring in another £500 million.
- Flagship plans to recruit approximately 50 scientist-entrepreneurs and operators in Britain initially.
Flagship puts £100 million behind company creation
The new unit, Flagship Origination Lab, U.K., will sit within Flagship Labs, the firm’s company-creation operation. Flagship says its teams will develop scientific ideas, test them, provide funding and build companies around them. The planned businesses will use AI across their work and pursue applications in human and planetary health, among other areas of science and technology.
Flagship has spent more than 25 years creating life-sciences companies and says it has formed more than 130, including Moderna. Noubar Afeyan, its founder and chief executive, said the London operation will create companies rather than buy stakes in existing ones. He plans to seek partners among universities, corporations and funders, Reuters reported.
Afeyan said the firm hopes its £100 million will draw £500 million or more from partners. Flagship’s announcement describes the £100 million as an initial commitment and the further £500 million as funding it anticipates attracting through partnerships. Flagship expects to hire and train an initial team of approximately 50 scientist-entrepreneurs and operators in Britain to work on the lab’s company-building programme.
London office becomes Flagship’s first overseas lab
Flagship opened an office in London in 2023, near the Francis Crick Institute in King’s Cross. That year it also signed a memorandum of understanding with the UK government to extend the reach of its companies, according to the firm. Flagship says its British work has since included research and development and partnerships involving universities, data and regulatory work.
Avak Kahvejian, president of Flagship Labs, said the firm chose Britain for its scientific research, clinical-trial infrastructure, genomics and health-data resources, and regulatory environment. Afeyan identified the National Health Service’s patient data as a particular draw. He said researchers could use evidence from patients to identify disease targets before beginning drug development.
Flagship says its existing British activity includes Quotient Therapeutics, which it describes as its first company spanning the United States and Britain. Its companies have also conducted clinical trials in Britain. Flagship says its London lab will develop and fund new companies.
Generate Biomedicines completes Manchester asthma trial
Afeyan said AI will be used throughout the London lab’s work, from developing an invention to running clinical trials. Flagship already has an example of AI-designed medicine being tested in Britain. Generate Biomedicines, one of its companies, completed an early-stage trial in Manchester of an AI-designed asthma drug, Reuters reported.
Afeyan cautioned that AI’s use in the field remains at an early stage. He said its first substantial contribution may be to help researchers understand the mechanisms of disease.